Sangamo Announces AAV Capsid Data

Uncategorized

PFIZER AND SANGAMO THERAPEUTICS ANNOUNCE PHASE 3 TRIAL OF INVESTIGATIONAL GENE THERAPY FOR HEMOPHILIA A HAS RE-OPENED RECRUITMENT

•    Patient dosing is expected to resume in October New York, NY, and Brisbane, California, September 22, 2022 – Pfizer and Sangamo Therapeutics announced that the Phase 3 AFFINE study evaluating giroctocogene fitelparvovec, an investigational gene therapy for patients with moderately severe to